natgillin/translations-raw huggingface dataset:
I nogle få tilfælde med meget høje plasmakoncentrationer har man effektivt kunnet reducere de toksiske koncentrationer med hæmofiltration eller hæmodiafiltration. 
In isolated patients with very high plasma levels, haemofiltration or -diafiltration have been effective in reducing toxic concentrations.
Efterfølgende har koncentrationerne i fuldblod generelt ligget på 5 - 15 ng/ml for lever-, nyre- og hjertetransplanterede patienter ved vedligeholdelsesbehandling. 
During subsequent maintenance therapy, blood concentrations have generally been in the range of 5 - 15 ng/ml in liver, kidney and heart transplant recipients.
Hos mennesker kan tacrolimus farmakokinetik efter intravenøs infusion bedst beskrives med en tocompartment model. 
In man, the disposition of tacrolimus after intravenous infusion may be described as biphasic.
Hyppigheden af biopsibekræftet akut afstødning inden for de første 24 timer efter transplantation var 32,6 % i Advagrafgruppen (N=237) og 29,3 % i Prografgruppen (N=234). 
The event rate of biopsy confirmed acute rejection within the first 24 weeks after transplantation was 32.6% in the Advagraf group (N=237) and 29.3% in the Prograf group (N=234).
Det er vanskeligt at fastslå bivirkningsprofilen ved immunsuppressiv behandling som følge af den tilgrundliggende lidelse og samtidig indtagelse af flere andre lægemidler. 
The adverse reaction profile associated with immunosuppressive agents is often difficult to establish owing to the underlying disease and the concurrent use of multiple medicinal products.
Epstein-Bar (EBV) og CMV-infektioner, knoglemarvsforøgelse, samtidig brug af interleukin 2antagonisten daclizumab, lavere initiale doser af tacrolimus med dalkoncentrationer på 10-15 ng/ml og senest bestråling af allotransplantat. 
A variety of innovations, such as techniques for early detection of Epstein-Barr (EBV) and CMV infections, bone marrow augmentation, the adjunct use of the interleukin-2 antagonist daclizumab, lower initial tacrolimus doses with target trough levels of 10 to 15 ng/ml, and most recently allograft irradiation were considered to have contributed to improved results in this indication over time.
Brug alle depotkapslerne inden for 1 år efter at aluminiumposen er åbnet. 
Use all the prolonged-release hard capsules within 1 year of opening the aluminium wrapping.
Sådan skal De tage Advagraf 
How to take Advagraf
Hos mennesker er det vist, at tacrolimus kan absorberes i hele mave-tarmkanalen. 
In man tacrolimus has been shown to be able to be absorbed throughout the gastrointestinal tract.
koagulationsforstyrrelser, pancytopeni, neutropeni, unormale koagulations- og blødningsanalyser 
coagulopathies, pancytopenia, neutropenia, coagulation and bleeding analyses, abnormal rare:
Overlevelsesraten efter 12 måneder var 98,6 % for Advagraf, 95,7 % for Prograf og 97,6 % for ciclosporin; i Advagrafgruppen døde 3 patienter (alle mænd), i Prografgruppen døde 10 patienter (3 kvinder, 7 mænd), og i ciclosporingruppen døde 6 patienter (3 kvinder, 3 mænd). 
The 12-month patient survival rates were 98.6% for Advagraf, 95.7% for Prograf and 97.6% for ciclosporin; in the Advagraf arm 3 patients died (all male), in the Prograf arm 10 patients died (3 female, 7 male) and in the ciclosporin arm 6 patients died (3 female, 3 male).
Transplantatoverlevelsen efter 12 måneder var 91,5 % for Advagraf og 92,8 % for Prograf. 
12-month graft survival was 91.5% for Advagraf and 92.8% for Prograf.
For at sikre en fyldestgørende eksponering i begyndelsen af den posttransplanterede periode anbefales det at overvåge tacrolimus' dalværdier omhyggeligt og hyppigt de første to uger med Advagraf efter transplantationen. 
Careful and frequent monitoring of tacrolimus trough levels is recommended in the first two weeks post-transplant with Advagraf to ensure adequate drug exposure in the immediate post-transplant period.
Meget almindelige bivirkninger (kan forekomme hos flere end 1 ud af 10 behandlede): - Forhøjet blodsukker, sukkersyge, øget kaliumindhold i blodet - Søvnløshed - Rysten, hovedpine 
Very common side effects (may affect more than 1 in 10 people): Increased blood sugar, diabetes mellitus, increased potassium in the blood Difficulty in sleeping
Da tacrolimus er et stof med lav clearance, kan det tage flere dage, inden steady state opnås efter justering af dosis. 
As tacrolimus is a substance with low clearance, adjustments to the Advagraf dose regimen may take several days before steady state is achieved.
Tacrolimus udviser embryo/føtal toksicitet hos rotter og kaniner ved doser, som var toksiske for moderen (se pkt. 
In rats and rabbits, tacrolimus caused embryofoetal toxicity at doses which demonstrated maternal toxicity (see section 5.3).
I plasma er tacrolimus stærkt bundet (>98,8 %) til plasmaproteiner, hovedsagelig til serumalbumin og surt alfa-1-glykoprotein. 
to plasma proteins, mainly to serum albumin and α-1-acid glycoprotein.
Printblækket, som bruges til at stemple Advagrafkapslen med, indeholder sojalecithin. 
The printing ink used to mark Advagraf capsules contains soya lecithin.
Kapselskal: Titandioxid (E171), gul jernoxid (E172), rød jernoxid (E172), natriumlaurilsulfat, gelatine. 
Capsule shell: Titanium dioxide (E171), yellow iron oxide (E 172), red iron oxide (E 172), sodium laurilsulfate, gelatin.
Overlevelsesraten efter 12 måneder var 96,9 % for Advagraf og 97,5 % for Prograf; i Advagrafgruppen døde 10 patienter (3 kvinder, 7 mænd), og i Prografgruppen døde 8 patienter (3 kvinder, 5 mænd). 
The 12-month patient survival rates were 96.9% for Advagraf and 97.5% for Prograf; in the Advagraf arm 10 patients died (3 female, 7 male) and in the Prograf arm 8 patients died (3 female, 5 male).
encefalopati, blødning i centralnervesystemet og hjerneblødning, koma, taleog sprogforstyrrelser, paralyse og pareser, amnesi 
encephalopathy, central nervous system haemorrhages and cerebrovascular accidents, coma, speech and language abnormalities, paralysis and paresis, amnesia rare:
Man bør udvise forsigtighed, når patienter skifter fra behandling med ciclosporin til tacrolimusbaseret behandling (se pkt. 
Care should be taken when converting patients from ciclosporin-based to tacrolimus-based therapy (see sections 4.4 and 4.5).
Tacrolimus metaboliseres i udstrakt grad i leveren, primært af CYP3A4. 
Tacrolimus is widely metabolised in the liver, primarily by the cytochrome P450-3A4.
Titandioxid (E 171) Gul jernoxid (E 172) Rød jernoxid (E 172) Natriumlaurilsulfat Gelatine. 
Titanium dioxide (E 171) Yellow iron oxide (E 172) Red iron oxide (E 172) Sodium laurilsulfate Gelatin.
Advagraf 0,5 mg depotkapsler, hårde Advagraf 1 mg depotkapsler, hårde Advagraf 3 mg depotkapsler, hårde Advagraf 5 mg depotkapsler, hårde tacrolimus 
Advagraf 0.5 mg prolonged-release hard capsules Advagraf 1 mg prolonged-release hard capsules Advagraf 3 mg prolonged-release hard capsules Advagraf 5 mg prolonged-release hard capsules
Hjælpestoffer, som behandleren skal være opmærksom på: hver kapsel indeholder 306,52 mg lactose. 
Excipients with known effect: Each capsule contains 306.52 mg lactose.
- Akut åndenød - Cystedannelse på bugspytkirtlen - Problemer med blodcirkulation i leveren - Alvorlig sygdom med blærer i huden, munden, øjnene og kønsorganerne, øget behåring - Tørst, øget tendens til at falde, trykken for brystet, nedsat bevægelighed, sår 
Cyst formation in your pancreas Problems with blood flow in the liver - Serious illness with blistering of skin, mouth, eyes and genitals; increased hairiness - Thirst, fall, feeling of tightness in your chest, decreased mobility, ulcer
Astellas Pharma B.V.Branch Belgique/Belgien Tél/Tel: + 32 (0)2 5580710 
Branch Belgique/Belgien Tél/Tel: + 32 (0)2 5580710
Tacrolimus blev startet som kontinuerlig intravenøs infusion med doser på 0,025 mg/kg/dag, oral tacrolimus blev administreret i doser på 0,15 mg/kg/dag med følgende dosisjustering for at nå dalkoncentrationer på 10-20 ng/ml. 
Tacrolimus was started as continuous intravenous infusion at a dose of 0.025 mg/kg/day and oral tacrolimus was administered at a dose of 0.15 mg/kg/day with subsequent dose adjustments to target trough levels of 10 to 20 ng/ml.
Indholdet af Advagraf i blodet kan påvirkes af anden medicin, og Advagraf kan påvirke indholdet af anden medicin i blodet. 
Advagraf blood levels can be affected by other medicines you take, and blood levels of other medicines can be affected by taking Advagraf, which may require interruption, an increase or a decrease in Advagraf dose.
Indehaver af markedsføringstilladelsen: Astellas Pharma Europe B.V. 
Marketing Authorisation Holder: Astellas Pharma Europe B.V. Sylviusweg 62
Hjælpestoffer, som behandleren skal være opmærksom på: hver kapsel indeholder 51,09 mg lactose. 
Excipients with known effect: Each capsule contains 51.09 mg lactose.
Fortæl det altid til lægen eller på apoteket, hvis De bruger anden medicin eller har gjort det for nylig. 
Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription and herbal preparations.
Sjældne bivirkninger (kan forekomme hos op til 1 ud af 1000 behandlede): - Små blødninger i huden - Øget muskelstivhed - Blindhed, døvhed - Væskeansamling omkring hjertet 
Rare side effects (may affect up to 1 in 1,000 people): Small bleedings in your skin due to blood clots Increased muscle stiffness
Tacrolimus startede som kontinuerlig intravenøs infusion med doser på 0,05 mg/kg/dag, hvorefter oral tacrolimus blev administreret i doser på 0,1 - 0,3 mg/kg/dag med følgende dosisjustering for at nå dalkoncentrationer på 12 - 15 ng/ml. 
Tacrolimus was started as continuous intravenous infusion at a dose of 0.05 mg/kg/day and oral tacrolimus was administered at a dose of 0.1 to 0.3 mg/kg/day with subsequent dose adjustments to target trough levels of 12 to 15 ng/ml.
Hjælpestoffer, som behandleren skal være opmærksom på: hver kapsel indeholder 102,17 mg lactose. 
Excipients with known effect: Each capsule contains 102.17 mg lactose.
dehydrering, hypoglykæmi, hypoproteinæmi, hyperfosfatæmi 
dehydration, hypoglycaemia, hypoproteinaemia, hyperphosphataemia Psychiatric disorders very common:
CYP3A4-hæmmere som potentielt kan øge tacrolimus' blodkoncentrationer Det er påvist, at de følgende midler øger tacrolimus' blodkoncentration: Der er set kraftige interaktioner med svampemidler som ketoconazol, fluconazol, itraconazol, voriconazol og isavuconazol, det macrolide antibiotikum erythromycin, HIV-protease-hæmmere (f.eks. ritonavir, nelfinavir, saquinavir), HCV-protease-hæmmere (f.eks. telaprevir, boceprevir og en kombination af ombitasvir og paritaprevir sammen med ritonavir, når det anvendes med og uden dasabuvir) eller det CMV antivirale letermovir, den farmakokinetiske forstærker cobicistat og tyrosinkinasehæmmerne nilotinib og imatinib. 
Strong interactions have been observed with antifungal agents such as ketoconazole, fluconazole, itraconazole, voriconazole and isavuconazole, the macrolide antibiotic erythromycin, HIV protease inhibitors (e.g. ritonavir, nelfinavir, saquinavir), HCV protease inhibitors (e.g. telaprevir, boceprevir, and the combination of ombitasvir and paritaprevir with ritonavir, when used with and without dasabuvir), or the CMV antiviral letermovir, the pharmacokinetic enhancer cobicistat, and the tyrosine kinase inhibitors nilotinib and imatinib.
Hjælpestoffer, som behandleren skal være opmærksom på: hver kapsel indeholder 510,9 mg lactose. 
Excipients with known effect: Each capsule contains 510.9 mg lactose.
Der er endnu ingen kliniske data tilgængelige for Advagraf ved profylaktisk behandling mod transplantatafstødning hos hjertetransplanterede voksne. 
For prophylaxis of transplant rejection in adult heart allograft recipients clinical data are not yet available for Advagraf.
øget fedtvæv 
Increased blood pressure
Patienter i immunsuppressiv behandling har en øget risiko for at få maligne lidelser. 
Neoplasms benign, malignant and unspecified Patients receiving immunosuppressive therapy are at increased risk of developing malignancies.
forstyrrelser i nervesystemet, krampeanfald, bevidsthedsforstyrrelser, perifer neuropati, svimmelhed, paræstesier og dysæstesier, nedsat skriveevne 
nervous system disorders seizures, disturbances in consciousness, peripheral neuropathies, dizziness, paraesthesias and dysaesthesias, writing impaired uncommon:
ledproblemer 
Kidney problems
målinger af serum-kreatininkoncentrationer, beregning af kreatininclearance og kontrol af diurese). 
However, owing to the nephrotoxic potential of tacrolimus careful monitoring of renal function is recommended (including serial serum creatinine concentrations, calculation of creatinine clearance and monitoring of urine output).
For at undertrykke transplantatafstødning skal immunsuppression vedligeholdes. 
To suppress graft rejection, immunosuppression must be maintained; consequently, no limit to the duration of oral therapy can be given.
symptomer fra mave-tarmkanalen, opkastning, abdominalsmerter, inflammatoriske lidelser i mave-tarmkanalen, blødning i mave-tarmkanalen, ulceration og perforation i mave-tarmkanalen, ascites, ulcerøs stomatitis, obstipation, dyspepsi, flatulens, oppustethed, tynd afføring 
gastrointestinal signs and symptoms, vomiting, gastrointestinal and abdominal pains, gastrointestinal inflammatory conditions, gastrointestinal haemorrhages, gastrointestinal ulceration and perforation, ascites, stomatitis and ulceration, constipation, dyspeptic signs and symptoms, flatulence, bloating and distension, loose stools uncommon:
erythromycin, clarithromycin, josamycin og rifampicin - letermovir, bruges til at forebygge sygdomme forårsaget af CMV (human cytomegalovirus) - HIV-protease-hæmmere (f.eks. ritonavir, nelfinavir, saquinavir), boostermedicinen cobicitstat og kombinationstabletter, som bruges ved behandling af HIV-infektion - HCV-protease-hæmmere (f.eks. telaprevir, boceprevir og kombinationen ombitasvir/paritaprevir/ritonavir med eller uden dasabuvir), som bruges til behandling af hepatitis C-infektion - nilotinib og imatinib (bruges til behandling af visse typer cancer) - mycophenolsyre, som bruges til at undertrykke immunsystemet for at forhindre afstødning af et transplantat - medicin til forebyggelse og behandling af mavesår og spiserørskatar (f.eks. omeprazol, 
In particular, you should tell your doctor if you are taking or have recently taken medicines like: - antifungal medicines and antibiotics, particularly so-called macrolide antibiotics, used to treat infections e.g. ketoconazole, fluconazole, itraconazole, voriconazole, clotrimazole, and isavuconazole, erythromycin, clarithromycin, josamycin, and rifampicin - letermovir, used to prevent illness caused by CMV (human cytomegalovirus) - HIV protease inhibitors (e.g ritonavir, nelfinavir, saquinavir), the booster medicine cobicistat, and combination tablets, used to treat HIV infection - HCV protease inhibitors (e.g. telaprevir, boceprevir, and the combination ombitasvir/paritaprevir/ritonavir with or without dasabuvir), used to treat hepatitis C infection - nilotinib and imatinib (used to treat certain cancers) - mycophenolic acid, used to suppress the immune system to prevent transplant rejection
Hver kapsel Advagraf 0,5 mg indeholder 0,5 mg tacrolimus (som monohydrat). 
Each capsule of Advagraf 0.5 mg contains 0.5 mg of tacrolimus (as monohydrate).
- Lægen har ordineret Advagraf til Dem personligt. 
- This medicine has been prescribed for you only.
lansoprazol eller cimetidin) - antiemetika, der anvendes til behandling af kvalme og opkastning (f.eks. metoclopramid) - cisaprid eller det syreneutraliserende middel magnesium-aluminium-hydroxid, der anvendes til behandling af halsbrand - p-piller eller anden hormonbehandling med ethinylestradiol, hormonbehandling med danazol - medicin mod forhøjet blodtryk eller hjerteproblemer (f.eks. nifedipin, nicardipin, diltiazem og verapamil) 
- medicines for stomach ulcer and acid reflux (e.g. omeprazole, lansoprazole or cimetidine) - antiemetics, used to treat nausea and vomiting (e.g. metoclopramide) - cisapride or the antacid magnesium-aluminium-hydroxide, used to treat heartburn - the contraceptive pill or other hormone treatments with ethinylestradiol, hormone treatments with danazol - medicines used to treat high blood pressure or heart problems (e.g. nifedipine, nicardipine, diltiazem and verapamil) - anti-arrhythmic drugs (amiodarone) used to control arrhythmia (uneven beating of the heart) - medicines known as “statins” used to treat elevated cholesterol and triglycerides - phenytoin or phenobarbital, used to treat epilepsy - the corticosteroids prednisolone and methylprednisolone, belonging to the class of corticosteroids used to treat inflammations or suppress the immune system (e.g. in transplant rejection) - nefazodone, used to treat depression
Hver kapsel Advagraf 1 mg indeholder 1 mg tacrolimus (som monohydrat). 
Each capsule of Advagraf 1 mg contains 1 mg of tacrolimus (as monohydrate).
30 depotkapsler, hårde 30×1 depotkapsler, hårde 50 depotkapsler, hårde 50×1 depotkapsler, hårde 60 depotkapsler, hårde 60×1 depotkapsler, hårde 100 depotkapsler, hårde 100×1 depotkapsler, hårde 
30 prolonged-release hard capsules 30×1 prolonged-release hard capsules 50 prolonged-release hard capsules 50×1 prolonged-release hard capsules 60 prolonged-release hard capsules 60×1 prolonged-release hard capsules 100 prolonged-release hard capsules 100×1 prolonged-release hard capsules
Advagraf 0,5 mg depotkapsler, hårde, med indhold af hvidt pulver er hårde gelatinekapsler præget med rødt ”0.5 mg” på den lysegule kapsel top og ”* 647” på den orange kapselbund. 
Advagraf 0.5 mg prolonged-release hard capsules are hard gelatin capsules imprinted in red with “0.5 mg” on the light yellow capsule cap and “ 647” on the orange capsule body, containing white powder.
Blodkoncentrationerne af ciclosporin og patientens tilstand skal tages i betragtning, før man indleder behandling med Advagraf. 
Advagraf therapy should be initiated after considering ciclosporin blood concentrations and the clinical condition of the patient.
Hver kapsel Advagraf 3 mg indeholder 3 mg tacrolimus (som monohydrat). 
Each capsule of Advagraf 3 mg contains 3 mg of tacrolimus (as monohydrate).
Hver kapsel Advagraf 5 mg indeholder 5 mg tacrolimus (som monohydrat). 
Each capsule of Advagraf 5 mg contains 5 mg of tacrolimus (as monohydrate).
Ikke almindelige bivirkninger (kan forekomme hos op til 1 ud af 100 behandlede): - Ændret blodstørkning, nedsat antal af alle typer af blodceller (ses i blodprøver) - Dehydrering, ophørt urinproduktion - Unormale resultater af blodprøver: Nedsat protein og sukker, øget fosfat, stigning i enzymet laktatdehydrogenase - Koma, blødning i hjernen, slagtilfælde, lammelse, forandringer i hjernen, tale- og sprogforstyrrelser, hukommelsesproblemer - Uklarhed af øjenlinsen, nedsat hørelse - Uregelmæssigt hjerteslag, hjertestop, hjertesvigt, forstyrrelser i hjertemuskulaturen, forstørret hjertemuskulatur, øget puls, unormalt EKG, unormalt hjerteslag og puls - Blodprop i vene i lemmerne, shock - Åndedrætsbesvær, lidelser i luftvejene, astma - Tarmslyng, øget blodniveau af enzymet amylase, tilbageløb af maveindhold, forsinket tømning af mavesækken - Betændelsestilstand i huden, brændende fornemmelse i sollys - Ledproblemer - Smertefuld menstruation og unormal menstruationsblødning - Multiorgansvigt, influenzalignende sygdom, øget temperaturfølsomhed, trykken for brystet, 
Common side effects (may affect up to 1 in 10 people): - Reduction in blood cell counts (platelets, red or white blood cells), increase in white blood cell counts, changes in red blood cell counts (seen in blood tests) Reduced magnesium, phosphate, potassium, calcium or sodium in the blood, fluid overload, increased uric acid or lipids in the blood, decreased appetite, increased acidity of the blood, other changes in the blood salts (seen in blood tests) - Anxiety symptoms, confusion and disorientation, depression, mood changes, nightmare, hallucination, mental disorders - Fits, disturbances in consciousness, tingling and numbness (sometimes painful) in the hands and feet, dizziness, impaired writing ability, nervous system disorders - Blurred vision, increased sensitivity to light, eye disorders Ringing sound in your ears
Advagraf 3 mg depotkapsler, hårde EU/1/07/387/011 
Advagraf 3 mg prolonged-release hard capsules EU/1/07/387/011
Advagraf 1 mg depotkapsler, hårde Tacrolimus 
Advagraf 1 mg prolonged-release hard capsules Tacrolimus
Advagraf 5 mg depotkapsler, hårde, med indhold af hvidt pulver er hårde gelatinekapsler præget med rødt ”5 mg” på den grå-røde kapseltop og ”* 687” på den orange kapselbund. 
Advagraf 5 mg prolonged-release hard capsules are hard gelatin capsules imprinted in red with “5 mg” on the greyish red capsule cap and “ 687” on the orange capsule body, containing white powder.
Overlevelsesraten efter 12 måneder var 89,2 % for Advagraf og 90,8 % for Prograf; i Advagrafgruppen døde 25 patienter (14 kvinder, 11 mænd), og i Prografgruppen døde 24 patienter (5 kvinder, 19 mænd). 
The treatment difference (Advagraf - Prograf) was 3.3% (95% confidence interval [5.7%, 12.3%]).The 12-month patient survival rates were 89.2% for Advagraf and 90.8% for Prograf; in the Advagraf arm 25 patients died (14 female, 11 male) and in the Prograf arm 24 patients died (5 female, 19 male).
Advagraf 0,5 mg depotkapsler, hårde Hver depotkapsel, hård, indeholder 0,5 mg tacrolimus (som monohydrat). 
Advagraf 0.5 mg prolonged-release hard capsules Each prolonged-release hard capsule contains 0.5 mg tacrolimus (as monohydrate).
30 depotkapsler, hårde 30×1 depotkapsler, hårde 50 depotkapsler, hårde 50×1 depotkapsler, hårde 100 depotkapsler, hårde 100×1 depotkapsler, hårde 
30 prolonged-release hard capsules 30×1 prolonged-release hard capsules 50 prolonged-release hard capsules 50×1 prolonged-release hard capsules 100 prolonged-release hard capsules 100×1 prolonged-release hard capsules
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE KARTON Advagraf 0,5 mg depotkapsler, hårde 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON Advagraf 0.5 mg prolonged-release hard capsules
Advagraf 1 mg depotkapsler, hårde, med indhold af hvidt pulver er hårde gelatinekapsler præget med rødt ”1 mg” på den hvide kapseltop og ”* 677” på den orange kapselbund. 
Advagraf 1 mg prolonged-release hard capsules are hard gelatin capsules imprinted in red with “1 mg” on the white capsule cap and “ 677” on the orange capsule body, containing white powder.
Advagraf 3 mg depotkapsler, hårde, med indhold af hvidt pulver er hårde gelatinekapsler præget med rødt ”3 mg” på den orange kapseltop og ”* 637” på den orange kapselbund. 
Advagraf 3 mg prolonged-release hard capsules are hard gelatin capsules imprinted in red with “3 mg” on the orange capsule cap and “ 637” on the orange capsule body, containing white powder.
Hver kapsel indeholder 0,5 mg tacrolimus (som monohydrat). 
Each capsule contains 0.5 mg tacrolimus (as monohydrate).
Tacrolimus blev startet som kontinuerlig intravenøs infusion i doser på 0,01 mg - 0,03 mg/kg/dag. 
Tacrolimus was started as continuous intravenous infusion at a dose of 0.01 to 0.03 mg/kg/day and oral tacrolimus was administered at a dose of 0.05 to 0.3 mg/kg/day.
Advagraf 1 mg depotkapsler, hårde Hver depotkapsel, hård, indeholder 1 mg tacrolimus (som monohydrat). 
Advagraf 1 mg prolonged-release hard capsules Each prolonged-release hard capsule contains 1 mg tacrolimus (as monohydrate).
I tilfælde af forhøjede ciclosporin-blodkoncentrationer bør doseringen udsættes. 
Dosing should be delayed in the presence of elevated ciclosporin blood levels.
Advagraf 3 mg depotkapsler, hårde Hver depotkapsel, hård, indeholder 3 mg tacrolimus (som monohydrat). 
Advagraf 3 mg prolonged-release hard capsules Each prolonged-release hard capsule contains 3 mg tacrolimus (as monohydrate).
MÆRKNING, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE KARTON Advagraf 1 mg depotkapsler, hårde 
PARTICULARS TO APPEAR ON THE OUTER PACKAGING CARTON Advagraf 1 mg prolonged-release hard capsules